VNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VolitionRX Ltd (VNRX) is not a strong buy for a beginner, long-term investor at this moment. While the company has promising technology and growth potential in the cancer detection market, the financial performance, technical indicators, and lack of strong trading signals suggest waiting for a clearer entry point.
The stock is showing bearish moving averages (SMA_200 > SMA_20 > SMA_5), with RSI at 39.988 in the neutral zone, and MACD positively contracting but still weak. The pre-market price is slightly down (-0.47%), and the stock is trading near its support level of 0.179.
The company has developed groundbreaking cancer detection technology (CTCF Capture-Seq™) with no false positives in validation studies. It estimates a $36 billion market potential and is pursuing partnerships for commercialization.
Financial performance shows a significant net income loss (-$5.37M) and declining EPS (-28.57% YoY). The stock has no recent trading signals, and hedge funds and insiders are neutral, indicating no strong institutional interest.
In Q3 2025, revenue increased by 32.19% YoY to $627,277, but net income dropped by 7.61% YoY to -$5,378,358. EPS also declined by 28.57% YoY to -0.05, reflecting ongoing financial struggles despite revenue growth.
No analyst rating or price target data is available for this stock.
